Leede Financial has initiated coverage of Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials NASDAQ:EPRX), assigning a “Buy” rating and a US $11.00 target price. Analyst Douglas Loe said the Victoria, B.C.-based biotechnology company’s proprietary drug-delivery platform positions it to “innovate meaningfully in autoimmune and inflammatory disease markets,” led by late-stage programs in […]
Research Capital analyst André Uddin re-initiated coverage of Spectral Medical (Spectral Medical Stock Quote, Chart, News, Analysts, Financials TSX:EDT) on Oct. 16 with a “Speculative Buy” rating and a C$3.50 price target, citing recent pivotal trial success, a large untapped U.S. market in septic shock, and a strong commercialization partner as key catalysts for a […]
Share
Tweet
Share
